We first focused on the frequency of CD4+ T cells (Th1, Th2, Th17 and Tregs) in the peripheral blood of 30 newly diagnosed untreated AML patients characterized by karyotype and molecular biology mutations (Table 1) and 30 sex- and age-matched HV. This evidence concerns the gene CD4 and acute myeloid leukemia.